ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,713.64
      1.70%
      US Tech 100
      19,304.00
      2.37%
      Dow Jones
      42,025.19
      1.26%
      Brent Oil
      74.32
      2.68%
      Bitcoin
      63,037.83
      2.22%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Aligos Therapeutics Inc (ALGS)

      7. Aligos Therapeutics Inc (ALGS) News

      ALGS

      Aligos Therapeutics (ALGS)

      Aligos Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:ALGS
      DateTimeSourceHeadlineSymbolCompany
      09/19/20248:00AMGlobeNewswire Inc.Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASHNASDAQ:ALGSAligos Therapeutics Inc
      09/18/20245:00PMGlobeNewswire Inc.Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024NASDAQ:ALGSAligos Therapeutics Inc
      09/13/20248:00AMGlobeNewswire Inc.Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ALGSAligos Therapeutics Inc
      09/06/20244:22PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALGSAligos Therapeutics Inc
      09/05/20244:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALGSAligos Therapeutics Inc
      08/19/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALGSAligos Therapeutics Inc
      08/15/20249:00AMGlobeNewswire Inc.Aligos Therapeutics Announces Reverse Stock SplitNASDAQ:ALGSAligos Therapeutics Inc
      08/09/20244:09PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALGSAligos Therapeutics Inc
      08/09/20244:08PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ALGSAligos Therapeutics Inc
      08/08/20244:11PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALGSAligos Therapeutics Inc
      08/08/20244:05PMGlobeNewswire Inc.Aligos Therapeutics Strengthens Board with Two New Independent DirectorsNASDAQ:ALGSAligos Therapeutics Inc
      08/06/20244:14PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALGSAligos Therapeutics Inc
      08/06/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALGSAligos Therapeutics Inc
      08/06/20244:05PMGlobeNewswire Inc.Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial ResultsNASDAQ:ALGSAligos Therapeutics Inc
      07/30/20244:05PMGlobeNewswire Inc.Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024NASDAQ:ALGSAligos Therapeutics Inc
      07/22/20249:00AMGlobeNewswire Inc.Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.NASDAQ:ALGSAligos Therapeutics Inc
      07/10/20248:00AMGlobeNewswire Inc.Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHBNASDAQ:ALGSAligos Therapeutics Inc
      06/05/20242:30AMGlobeNewswire Inc.Aligos Therapeutics Presents Positive Data at the EASL Congress 2024NASDAQ:ALGSAligos Therapeutics Inc
      05/31/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALGSAligos Therapeutics Inc
      05/22/20244:05PMGlobeNewswire Inc.Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024NASDAQ:ALGSAligos Therapeutics Inc
      05/22/20244:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALGSAligos Therapeutics Inc
      05/21/20248:00AMGlobeNewswire Inc.Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASHNASDAQ:ALGSAligos Therapeutics Inc
      05/15/20245:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALGSAligos Therapeutics Inc
      05/07/20244:13PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALGSAligos Therapeutics Inc
      05/07/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALGSAligos Therapeutics Inc
      05/07/20244:05PMGlobeNewswire Inc.Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial ResultsNASDAQ:ALGSAligos Therapeutics Inc
      04/30/20244:05PMGlobeNewswire Inc.Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024NASDAQ:ALGSAligos Therapeutics Inc
      04/25/20244:05PMGlobeNewswire Inc.Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 StudyNASDAQ:ALGSAligos Therapeutics Inc
      04/25/20248:00AMGlobeNewswire Inc.Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MDNASDAQ:ALGSAligos Therapeutics Inc
      04/09/20248:00AMGlobeNewswire Inc.Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024NASDAQ:ALGSAligos Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:ALGS